Despite growing pressure from lawmakers over the pharmaceutical industry’s pricey products, new research shows that pharma relied largely on price hikes for growth in 2016. A 120-page report from Credit Suisse demonstrated that net price growth made up 100% of net income growth for a variety of companies within the industry, including Biogen (NSDQ:BIIB), Eli Lilly […]
Biogen
Trump FDA pick to recuse himself from agency decisions involving 20 companies
Donald Trump’s nominee to head the FDA, Dr. Scott Gottlieb, reportedly told ethics officials at the Office of Government Ethics he plans to recuse himself for 1 year from agency decisions on more than 20 companies, including GlaxoSmithKline (NYSE:GSK) and Bristol-Myers Squibb (NYSE:BMY). Gottlieb has received millions of dollars for his roles as advisor, paid speaker […]
Ocular Therapeutix CFO Smith departs | Personnel Moves – March 21, 2017
Ocular Therapeutix (NSDQ:OCUL) said yesterday that its chief financial officer, Bradford Smith, will resign from the company at the end of this month. James Fortune, Ocular’s chief operating officer, will assume the roles of principal financial officer and principal accounting officer, according to a regulatory filing. Get the full story at our sister site, Drug Delivery […]
Pharma stocks fall on Trump’s proposal to cut NIH budget
The Trump budget plan to slash more than 18% from the budget for the National Institutes of Health sent pharmaceutical stocks down today on Wall Street as investors reacted to the proposal. The budget proposal, released today, would cut the NIH budget by $5.8 billion, to $25.9 billion – an 18.3% cut. The proposal would also introduce […]
7 medtech stories we missed: Feb. 3, 2017
From disappointing Getinge earnings to a $2.25 billion U.S. Defense Department contract for Cardinal Health to a host of 510(k) clearances, here are seven recent medtech stories that are still worth a mention. 1. Getinge disappoints on earnings—again Getinge stock took a nearly 10% tumble last week after releasing earnings that Reuters says lagged analyst […]
Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy. In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen […]
Biogen beats Q4 earnings, misses on full-year rev forecast
Shares in Biogen (NSDQ:BIIB) rose this week after the biopharmaceutical company met expectations on Wall Street with its 4th quarter financial results, but pegged its full-year revenue forecast lower than analysts expected. The Cambridge, Mass.-based company posted profits of $649.2 million, or $2.99 per share, on sales of $2.87 billion for the 3 months ended Dec. […]
Zimmer Biomet elevates Delp to Americas prez | Personnel Moves | January 22, 2017
Zimmer Biomet (NYSE:ZBH) said this week it tapped Robert Delp as its new Americas president, lifting him from his previous position as VP of US sales. Delp will replace former Americas prez Stuart Kleopfer, who is retiring from the position but will continue to work with the company while Delp transitions into his position. The shift […]
Biogen, Ionis win FDA approval for first spinal muscular atrophy drug
Biogen (NSDQ:BIIB) said last week that it won FDA approval for its spinal muscular atrophy treatment, Spinraza. The drug is the 1st treatment approved in the U.S. for spinal muscular atrophy, a progressive and often fatal genetic disease that causes muscle weakness in infants and toddlers. The FDA previously granted Biogen’s application fast track designation […]
Changing healthcare & clinical trials with patient monitoring tech
Patient monitoring can be challenging, often relying on patients to self-report symptoms or describe how they’re feeling. But technology is changing that, making it easier for researchers to monitor patient adherence to a trial’s regimen and for doctors to personalize a patient’s treatment. At the FierceBiotech Drug Development Forum in Boston today, a panel took up the […]
Schellhorn out, Emerson in as Monteris CEO | Personnel Moves July 25, 2016
Schellhorn out, Emerson in as Monteris CEO Monteris Medical said last week it tapped ex-Galil Medical prez & CEO Martin Emerson as its new president and chief executive officer, replacing John Schellhorn who left earlier this year. Emerson spent 8 years as prez & CEO of Galil Medical, which was acquired in June this year […]